Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-586b7cd67f-g8jcs Total loading time: 0 Render date: 2024-11-25T08:48:23.106Z Has data issue: false hasContentIssue false

Chapter 11 - Case Studies of Basket Trials and Umbrella Trials

from Part IV - Case Studies of Adaptive Trial Designs and Master Protocols

Published online by Cambridge University Press:  20 March 2023

Jay J. H. Park ,
Edward J. Mills  and
J. Kyle Wathen
By
Jay J. H. Park ,
Edward J. Mills  and
J. Kyle Wathen
Jay J. H. Park
Affiliation:
McMaster University, Ontario
Edward J. Mills
Affiliation:
McMaster University, Ontario
J. Kyle Wathen
Affiliation:
Cytel, Cambridge, Massachusetts
Get access

Summary

In this chapter, we review six case studies of basket and umbrella trials. This chapter is intended to complement the previous chapters on master protocols and basket and umbrella trials.

Keywords

basket trialsumbrella trialsprecision medicineprecison oncologyNCI-MATCHNCI-MPACTplasmaMATCHALCHEMISTLung-MAP
Type
Chapter
Information
Introduction to Adaptive Trial Designs and Master Protocols , pp. 127 - 139
Publisher: Cambridge University Press
Print publication year: 2023

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Connell, CM, Doherty, GJ. Activating HER2 mutations as emerging targets in multiple solid cancers. ESMO Open. 2017;2(5):e000279.CrossRefGoogle ScholarPubMed
Verma, S, Miles, D, Gianni, L, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med. 2012;367(19):1783–91.Google Scholar
Amiri-Kordestani, L, Blumenthal, GM, Xu, QC, et al. FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res. 2014;20(17):4436–41.Google ScholarPubMed
Li, BT, Shen, R, Buonocore, D, et al. Ado-trastuzumab emtansine for patients with HER2-mutant lung cancers: results from a phase II basket trial. J Clin Oncol. 2018;36(24):2532–7.Google Scholar
Li, BT, Makker, V, Buonocore, DJ, et al. A multi-histology basket trial of ado-trastuzumab emtansine in patients with HER2 amplified cancers. J Clin Oncol. 2018;36(15_suppl):2502.CrossRefGoogle Scholar
Eisenhauer, EA, Therasse, P, Bogaerts, J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228–47.Google Scholar
Simon, R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials. 1989;10(1):1–10.CrossRefGoogle ScholarPubMed
Park, JJ, Harari, O, Dron, L, Mills, EJ, Thorlund, K. Effects of biomarker diagnostic accuracy on biomarker-guided phase 2 trials. Contemp Clin Trials Commun. 2019;15:100396.Google Scholar
Conley, BA, Doroshow, JH. Molecular analysis for therapy choice: NCI MATCH. Semin Oncol. 2014;41(3):297–9.Google Scholar
Mullard, A. NCI-MATCH trial pushes cancer umbrella trial paradigm. Nat Rev Drug Discov. 2015;14(8):513–5.Google ScholarPubMed
Chen, A, Conley, B, Hamilton, S, et al. NCI-Molecular Analysis for Therapy Choice (NCI-MATCH) trial: a novel public-private partnership. Eur J Cancer. 2016;69:S137.CrossRefGoogle Scholar
Moore, KN, Mannel, RS. Is the NCI MATCH trial a match for gynecologic oncology? Gynecol Oncol. 2016;140(1):161–6.CrossRefGoogle Scholar
Abrams, J, Conley, B, Mooney, M, et al. National Cancer Institute’s Precision Medicine Initiatives for the new National Clinical Trials Network. Am Soc Clin Oncol Educ Book. 2014:71–6.CrossRefGoogle Scholar
Barroilhet, L, Matulonis, U. The NCI-MATCH trial and precision medicine in gynecologic cancers. Gynecol Oncol. 2018;148(3):585–90.Google Scholar
Chae, YK, Hong, F, Vaklavas, C, et al. Phase II study of AZD4547 in patients with tumors harboring aberrations in the FGFR pathway: results from the NCI-MATCH trial (EAY131) subprotocol W. J Clin Oncol. 2020;38(21):2407–17.Google Scholar
Mansfield, AS, Wei, Z, Mehra, R, et al. Crizotinib in patients with tumors harboring ALK or ROS1 rearrangements in the NCI-MATCH trial. NPJ Precis Oncol. 2022;6(1):13.Google Scholar
Van Cutsem, E, Bang, YJ, Mansoor, W, et al. A randomized, open-label study of the efficacy and safety of AZD4547 monotherapy versus paclitaxel for the treatment of advanced gastric adenocarcinoma with FGFR2 polysomy or gene amplification. Ann Oncol. 2017;28(6):1316–24.CrossRefGoogle ScholarPubMed
Aggarwal, C, Redman, MW, Lara, PN, Jr., et al. SWOG S1400D (NCT02965378), a phase II study of the fibroblast growth factor receptor inhibitor AZD4547 in previously treated patients with fibroblast growth factor pathway-activated stage IV squamous cell lung cancer (Lung-MAP Substudy). J Thorac Oncol. 2019;14(10):1847–52.Google Scholar
Aggarwal, C, Redman, MW, Lara, P, et al. Phase II study of the FGFR inhibitor AZD4547 in previously treated patients with FGF pathway-activated stage IV squamous cell lung cancer (SqNSCLC): LUNG-MAP sub-study SWOG S1400D. J Clin Oncol. 2017;35(15 suppl).Google Scholar
Aggarwal, C, Redman, MW, Lara, PN, Jr et al. SWOG S1400D (NCT02965378), a phase II study of the fibroblast growth factor receptor inhibitor AZD4547 in previously treated patients with fibroblast growth factor pathway–activated stage IV squamous cell lung cancer (Lung-MAP substudy). J Thorac Oncol. 2010;14(10):1847–1852.Google Scholar
Lih, CJ, Takebe, N. Considerations of developing an NGS assay for clinical applications in precision oncology: The NCI-MATCH NGS assay experience. Curr Probl Cancer. 2017;41(3):201–11.Google Scholar
Kummar, S, Williams, M, Lih, C-J, et al. NCI mpact: National Cancer Institute molecular profiling-based assignment of cancer therapy. J Clin Oncol. 2014;32(15).Google Scholar
Chen, AP, Kummar, S, Moore, N, et al. Molecular Profiling-Based Assignment of Cancer Therapy (NCI-MPACT): a randomized multicenter phase II trial. JCO Precis Oncol. 2021;5.Google Scholar
Turner, N, Bye, H, Kernaghan, S, et al. Abstract OT1-06-03: The plasmaMATCH trial: A multiple parallel cohort, open-label, multi-centre phase II clinical trial of ctDNA screening to direct targeted therapies in patients with advanced breast cancer (CRUK/15/010). Cancer Res. 2018;78(4 Supplement):OT1-06-3-OT1–3.Google Scholar
Cancer Research UK. A trial using a blood test to find certain gene changes and decide treatment for advanced breast cancer (plasmaMATCH). 2019. www.cancerresearchuk.org/about-cancer/find-a-clinical-trial/a-trial-using-a-blood-test-to-find-certain-gene-changes-and-decide-treatment-for-advanced-breast#undefinedGoogle Scholar
Kingston, B, Cutts, RJ, Bye, H, et al. Genomic profile of advanced breast cancer in circulating tumour DNA. Nat Commun. 2021;12(1):2423.Google Scholar
Turner, NC, Kingston, B, Kilburn, LS, et al. Circulating tumour DNA analysis to direct therapy in advanced breast cancer (plasmaMATCH): a multicentre, multicohort, phase 2a, platform trial. Lancet Oncol. 2020;21(10):1296–308.Google Scholar
Covens, AL, Filiaci, V, Gersell, D, et al. Phase II study of fulvestrant in recurrent/metastatic endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2011;120(2):185–8.Google Scholar
Rabindran, SK, Discafani, CM, Rosfjord, EC, et al. Antitumor activity of HKI-272, an orally active, irreversible inhibitor of the HER-2 tyrosine kinase. Cancer Res. 2004;64(11):3958–65.Google Scholar
Fong, PC, Boss, DS, Yap, TA, et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med. 2009;361(2):123–34.Google Scholar
Govindan, R, Mandrekar, SJ, Gerber, DE, Ox, , et al. ALCHEMIST trials: a golden opportunity to transform outcomes in early-stage non-small cell lung cancer. Clin Cancer Res. 2015;21(24):5439–44.Google Scholar
Kehl, KL, Zahrieh, D, Yang, P, et al. Rates of guideline-concordant surgery and adjuvant chemotherapy among patients with early-stage lung cancer in the US ALCHEMIST study (Alliance A151216). JAMA Oncol. 2022;8(5):717–28.Google Scholar
Chaft, JE, Dahlberg, SE, Khullar, OV, et al. EA5142 adjuvant nivolumab in resected lung cancers (ANVIL). J Clin Oncol. 2018;35(15).Google Scholar
Sands, J, Mandrekar, SJ, Oxnard, GR, K, et al. ALCHEMIST: Adjuvant targeted therapy or immunotherapy for high-risk resected NSCLC. J Clin Oncol. 2020;28(15 suppl).Google Scholar
Ferrarotto, R, Redman, MW, Gandara, DR, Herbst, RS, Papadimitrakopoulou, VA. Lung-MAP – framework, overview, and design principles. Chin Clin Oncol. 2015;4(3):36.Google Scholar
SWOG Cancer Research Network. A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (Lung-MAP Screening Study). 2019. www.swog.org/clinical-trials/lungmapGoogle Scholar
Papadimitrakopoulou, V, Redman, M, Borghaei, H, et al. 83OA phase II study of durvalumab (MEDI4736) for previously treated patients with stage IV squamous NSCLC (SqNSCLC): Lung-MAP Sub-study SWOG S1400A. Ann Oncol. 2017;28(suppl_2).Google Scholar
Wade, JL, Langer, CJ, Redman, M, et al. A phase II study of GDC-0032 (taselisib) for previously treated PI3 K positive patients with stage IV squamous cell lung cancer (SqNSCLC): LUNG-MAP sub-study SWOG S1400B. J Clin Oncol. 2017;35(15).Google Scholar
Edelman, MJ, Redman, MW, Albain, KS, et al. A phase II study of palbociclib (P) for previously treated cell cycle gene alteration positive patients (pts) with stage IV squamous cell lung cancer (SCC): Lung-MAP sub-study SWOG S1400C. J Clin Oncol. 2017;35(15).Google Scholar
Borghaei, H, Redman, MW, Kelly, K, et al. SWOG S1400A (NCT02154490): a phase II study of durvalumab for patients with previously treated stage IV or recurrent squamous cell lung cancer (Lung-MAP sub-study). Clin Lung Cancer. 2021;22(3):178–86.Google Scholar
Langer, CJ, Redman, MW, Wade, JL, 3rd, et al. SWOG S1400B (NCT02785913), a phase ii study of GDC-0032 (taselisib) for previously treated PI3 K-positive patients with stage IV squamous cell lung cancer (Lung-MAP sub-study). J Thorac Oncol. 2019;14(10):1839–46.CrossRefGoogle Scholar
Edelman, MJ, Redman, MW, Albain, KS, et al. SWOG S1400C (NCT02154490) – a phase II study of palbociclib for previously treated cell cycle gene alteration-positive patients with stage IV squamous cell lung cancer (Lung-MAP substudy). J Thorac Oncol. 2019;14(10):1853–9.Google Scholar
Leighl, NB, Redman, MW, Rizvi, N, et al. Phase II study of durvalumab plus tremelimumab as therapy for patients with previously treated anti-PD-1/PD-L1 resistant stage IV squamous cell lung cancer (Lung-MAP substudy S1400F, NCT03373760). J Immunother Cancer. 2021;9(8).CrossRefGoogle ScholarPubMed
Owonikoko, TK, Redman, MW, Byers, LA, et al. Phase 2 study of talazoparib in patients with homologous recombination repair-deficient squamous cell lung cancer: Lung-MAP substudy S1400G. Clin Lung Cancer. 2021;22(3):187–94 e1.Google Scholar
Gettinger, SN, Redman, MW, Bazhenova, L, et al. Nivolumab plus ipilimumab vs nivolumab for previously treated patients with stage IV squamous cell lung cancer: the Lung-MAP S1400I phase 3 randomized clinical trial. JAMA Oncol. 2021;7(9):1368–77.CrossRefGoogle ScholarPubMed
Waqar, SN, Redman, MW, Arnold, SM, et al. A phase II study of telisotuzumab vedotin in patients with c-MET-positive stage IV or recurrent squamous cell lung cancer (LUNG-MAP Sub-study S1400 K, NCT03574753). Clin Lung Cancer. 2021;22(3):170–7.Google Scholar
Roth, JA, Trivedi, MS, Gray, SW, et al. Patient knowledge and expectations about return of genomic results in a biomarker-driven master protocol trial (SWOG S1400GEN). JCO Oncology Pract. 2021;17(11):e1821–e9.Google Scholar
Redman, MW, Papadimitrakopoulou, VA, Minichiello, K, et al. Biomarker-driven therapies for previously treated squamous non-small-cell lung cancer (Lung-MAP SWOG S1400): a biomarker-driven master protocol. Lancet Oncol. 2020;21(12):1589–601.CrossRefGoogle ScholarPubMed

Save book to Kindle

To save this book to your Kindle, first ensure [email protected] is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×